ID: ALA1339340

Max Phase: Preclinical

Molecular Formula: C14H12N2O3S2

Molecular Weight: 320.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc2nc(-c3ccc(N)cc3)sc2c1S(=O)(=O)O

Standard InChI:  InChI=1S/C14H12N2O3S2/c1-8-2-7-11-12(13(8)21(17,18)19)20-14(16-11)9-3-5-10(15)6-4-9/h2-7H,15H2,1H3,(H,17,18,19)

Standard InChI Key:  KGZUHYIHYBDNLC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 320.40

Molecular Weight (Monoisotopic): 320.0289

AlogP: 3.10

#Rotatable Bonds: 2

Polar Surface Area: 93.28

Molecular Species: ACID

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: -3.17

CX Basic pKa: 2.93

CX LogP: 2.67

CX LogD: 0.63

Aromatic Rings: 3

Heavy Atoms: 21

QED Weighted: 0.56

Np Likeness Score: -1.11

References

1. PubChem BioAssay data set, 

2. Iqbal J, Saeed A, Raza R, Matin A, Hameed A, Furtmann N, Lecka J, Sévigny J, Bajorath J..  (2013)  Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.,  70  [PMID:24215819] [10.1016/j.ejmech.2013.10.053]

3. PubChem BioAssay data set, 

4. Amin SA,Banerjee S,Gayen S,Jha T.  (2021)  Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?,  215  [PMID:33618158] [10.1016/j.ejmech.2021.113294]

5. Pillaiyar T, Manickam M, Namasivayam V, Hayashi Y, Jung SH..  (2016)  An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.,  59  (14): [PMID:26878082] [10.1021/acs.jmedchem.5b01461]

Source

Source(2):

• Scientific Literature
• PubChem BioAssays